HCW Biologics Reports Positive Preliminary Human Data for HCW9302 Phase 1 Trial in Alopecia Areata

HCW Biologics Inc.

All three patients in second dose cohort (3 µg/kg) showed ≥25% reduction in SALT scores after single dose, indicating clinical response.
No dose-limiting toxicities, capillary leak, cytokine release syndrome, or increased eosinophil counts reported; only mild injection-site reactions.
Company projects to establish Recommended Phase 2 Dose by year-end 2026 and is dosing third cohort (8 µg/kg).
HCW9302 is a first-in-kind IL-2 based fusion immunotherapeutic with strong IL-2Rα bias, potentially best-in-class for autoimmune diseases.
CEO Hing C. Wong stated results consistent with preclinical studies showing Treg expansion and reduced inflammation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.